$CYDY
CytoDyn Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023016632 Filed on October 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $2.688M
YoY Change -57.56%
% of Gross Profit
Research & Development $1.914M
YoY Change 232.29%
% of Gross Profit
Depreciation & Amortization $10.00K
YoY Change -89.9%
% of Gross Profit
Operating Expenses $1.914M
YoY Change 232.29%
Operating Profit -$4.612M
YoY Change -52.51%
Interest Expense -$1.959M
YoY Change -81.05%
% of Operating Profit
Other Income/Expense, Net -$912.0K
YoY Change -2.98%
Pretax Income -$11.57M
YoY Change -44.88%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.57M
YoY Change -44.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 931.0M
Diluted Shares Outstanding 923.6M

Balance Sheet

Concept 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.034M
YoY Change -56.5%
Cash & Equivalents $2.034M
Short-Term Investments
Other Short-Term Assets $9.934M
YoY Change 91.74%
Inventory
Prepaid Expenses $2.858M
Receivables
Other Receivables
Total Short-Term Assets $11.97M
YoY Change 21.42%
LONG-TERM ASSETS
Property, Plant & Equipment $366.0K
YoY Change -27.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $443.0K
YoY Change -27.14%
Total Long-Term Assets $443.0K
YoY Change -97.61%
TOTAL ASSETS
Total Short-Term Assets $11.97M
Total Long-Term Assets $443.0K
Total Assets $12.41M
YoY Change -56.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $62.80M
YoY Change -8.99%
Accrued Expenses $26.23M
YoY Change 59.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $33.10M
YoY Change -10.13%
Total Short-Term Liabilities $129.1M
YoY Change 5.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $247.0K
YoY Change -36.18%
Total Long-Term Liabilities $247.0K
YoY Change -36.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $129.1M
Total Long-Term Liabilities $247.0K
Total Liabilities $129.3M
YoY Change 5.37%
SHAREHOLDERS EQUITY
Retained Earnings -$853.3M
YoY Change 9.0%
Common Stock $931.0K
YoY Change 14.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$116.9M
YoY Change
Total Liabilities & Shareholders Equity $12.41M
YoY Change -56.29%

Cashflow Statement

Concept 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.57M
YoY Change -44.88%
Depreciation, Depletion And Amortization $10.00K
YoY Change -89.9%
Cash From Operating Activities -$4.495M
YoY Change -59.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.019M
YoY Change -65.11%
NET CHANGE
Cash From Operating Activities -4.495M
Cash From Investing Activities 0.000
Cash From Financing Activities 4.019M
Net Change In Cash -476.0K
YoY Change -206.97%
FREE CASH FLOW
Cash From Operating Activities -$4.495M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001175680
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
923587000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
787856000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20230831#AccruedCompensationAndNonFinancingLiabilities
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023Q3 cydy Number Of Days Of Notice To Be Given For Conversion Of Notes Into Common Stock
NumberOfDaysOfNoticeToBeGivenForConversionOfNotesIntoCommonStock
P5D
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.cytodyn.com/20230831#AccruedCompensationAndNonFinancingLiabilities
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-49908
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
CYTODYN INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1887078
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Main Street
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 660
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98660
CY2023Q3 dei City Area Code
CityAreaCode
360
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
980-8524
CY2023Q3 dei Security12b Title
Security12bTitle
None
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
931151762
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2034000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2541000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6538000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6507000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2858000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1167000
CY2023Q3 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
538000
CY2023Q2 cydy Prepaid Service Fees Current
PrepaidServiceFeesCurrent
590000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11968000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
10805000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
443000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
487000
CY2023Q3 us-gaap Assets
Assets
12411000
CY2023Q2 us-gaap Assets
Assets
11292000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
62773000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
62725000
CY2023Q3 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
8777000
CY2023Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
6669000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
11772000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
10598000
CY2023Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
5681000
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
5308000
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
33100000
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
34417000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4375000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
79000
CY2023Q3 cydy Private Placement Of Shares And Warrants
PrivatePlacementOfSharesAndWarrants
2575000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
129053000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
119796000
CY2023Q2 us-gaap Notes Payable
NotesPayable
714000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
247000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283000
CY2023Q3 us-gaap Liabilities
Liabilities
129300000
CY2023Q2 us-gaap Liabilities
Liabilities
120793000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1350000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1350000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
931400000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
919053000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
930957000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
918610000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
931000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
919000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
443000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
735441000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
731270000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-853261000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-841690000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-116889000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-109501000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12411000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11292000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2688000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6333000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1914000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
576000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
99000
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
2704000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
4612000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
9712000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4612000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9712000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1197000
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1146000
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
576000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
366000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
16000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2023Q3 cydy Finance Charge Adjustments
FinanceChargeAdjustments
912000
CY2022Q3 cydy Finance Charge Adjustments
FinanceChargeAdjustments
940000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2084000
CY2023Q3 cydy Gain Loss On Derivatives
GainLossOnDerivatives
4000
CY2022Q3 cydy Gain Loss On Derivatives
GainLossOnDerivatives
-8601000
CY2023Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
6959000
CY2022Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
11279000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11571000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20991000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20991000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923587000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
923587000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
787856000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
787856000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-109501000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1500000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
170000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2023Q3 cydy Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
300000
CY2023Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
373000
CY2023Q3 cydy Reclassification Of Warrants From Liability To Equity Classified
ReclassificationOfWarrantsFromLiabilityToEquityClassified
79000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-116889000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-94398000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
345000
CY2022Q3 cydy Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Excluding Legal Fees
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsExcludingLegalFees
6289000
CY2022Q3 cydy Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
264000
CY2022Q3 cydy Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends
AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends
384000
CY2022Q3 cydy Reclassification Of Warrants From Liability To Equity Classified
ReclassificationOfWarrantsFromLiabilityToEquityClassified
8601000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
996000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20991000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-94312000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20991000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
99000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
366000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
16000
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
576000
CY2023Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
4000
CY2022Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-8601000
CY2023Q3 cydy Loss On Induced Conversion Of Debt
LossOnInducedConversionOfDebt
2004000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2084000
CY2022Q3 us-gaap Inventory Write Down
InventoryWriteDown
2704000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
503000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1341000
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1605000
CY2022Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1601000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3318000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1819000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4495000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11074000
CY2023Q3 cydy Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
2575000
CY2022Q3 cydy Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
11255000
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000
CY2022Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
264000
CY2023Q3 cydy Proceeds From Convertible Note And Warrant Issuances
ProceedsFromConvertibleNoteAndWarrantIssuances
1144000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4019000
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11519000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-476000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
445000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9048000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4231000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8572000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4676000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2034000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4676000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6538000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8572000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4676000
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
24000
CY2023Q3 cydy Noncash Derivative Liability Associated With Warrants
NoncashDerivativeLiabilityAssociatedWithWarrants
83000
CY2022Q3 cydy Noncash Derivative Liability Associated With Warrants
NoncashDerivativeLiabilityAssociatedWithWarrants
8601000
CY2023Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1500000
CY2023Q3 cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
373000
CY2022Q3 cydy Dividends On Convertible Preferred Stock Incurred But Not Yet Paid.
DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.
384000
CY2023Q3 cydy Warrants Issued To Placement Agent
WarrantsIssuedToPlacementAgent
413000
CY2022Q3 cydy Warrants Issued To Placement Agent
WarrantsIssuedToPlacementAgent
4491000
CY2022Q3 cydy Common Stock Issued Related To Modification Of Equity Agreements
CommonStockIssuedRelatedToModificationOfEquityAgreements
4154000
CY2023Q3 cydy Note Conversion To Common Stock And Warrants
NoteConversionToCommonStockAndWarrants
2295000
CY2023Q3 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
8777000
CY2023Q2 cydy Accrued Compensation And Non Financing Liabilities
AccruedCompensationAndNonFinancingLiabilities
6669000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25530000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923587000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
787856000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q3 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Reclassifications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain prior year and prior quarter amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation. Such reclassifications did not have a material effect on the Company’s previously reported financial position, results of operations, stockholders’ deficit, or net cash provided by operating activities.</p>
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-853300000
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in accordance with accounting principles GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and/or discussions with the FDA which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various market and other relevant, appropriate assumptions. Significant estimates include, but are not limited to, those relating to capitalization of pre-launch inventories, charges for excess and obsolete inventories, research and development expenses, commitments and contingencies, stock-based compensation, and the assumptions used to value warrants and warrant modifications. Actual results could differ from these estimates. </p>
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6500000
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 cydy Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.12
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
62800000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
62700000
CY2023Q3 cydy Number Of Counterparties
NumberOfCounterparties
2
CY2023Q2 cydy Number Of Counterparties
NumberOfCounterparties
2
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
349000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
335000
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
239000
CY2023Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
168000
CY2023Q3 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
1084000
CY2023Q2 cydy Accrued Clinical Expenses
AccruedClinicalExpenses
187000
CY2023Q3 cydy Accrued Inventory Charges Current
AccruedInventoryChargesCurrent
5866000
CY2023Q2 cydy Accrued Inventory Charges Current
AccruedInventoryChargesCurrent
4978000
CY2023Q3 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
1096000
CY2023Q2 cydy Accrued License Fees Current
AccruedLicenseFeesCurrent
862000
CY2023Q3 cydy Accrued Lease Payable
AccruedLeasePayable
140000
CY2023Q2 cydy Accrued Lease Payable
AccruedLeasePayable
139000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
33950000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
36450000
CY2023Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
850000
CY2023Q2 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
1319000
CY2023Q3 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
33100000
CY2023Q2 cydy Long Term Debt Including Accrued Interest
LongTermDebtIncludingAccruedInterest
35131000
CY2023Q3 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
11772000
CY2023Q2 cydy Accrued Interest Noncurrent
AccruedInterestNoncurrent
10598000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
44872000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
45729000
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
45729000
CY2023Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
975000
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
766000
CY2023Q3 cydy Interest Expense Accrued
InterestExpenseAccrued
1197000
CY2023Q3 cydy Debt Conversion Fair Market Value Of Shares Exchanged For Repayment
DebtConversionFairMarketValueOfSharesExchangedForRepayment
6383000
CY2023Q3 cydy Changes In Fair Value Of Common Stocks Of Convertible Debt
ChangesInFairValueOfCommonStocksOfConvertibleDebt
2588000
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
44872000
CY2023Q2 cydy Number Of Share In Unit
NumberOfShareInUnit
1
CY2023Q2 cydy Number Of Warrant In Unit
NumberOfWarrantInUnit
1
CY2023Q2 cydy Deemed Purchase Price As Percentage Of Lower Intraday Volume Weighted Average Price
DeemedPurchasePriceAsPercentageOfLowerIntradayVolumeWeightedAveragePrice
0.90
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.306
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2023Q3 cydy Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.12
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.306
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
79000
CY2023Q3 cydy Derivative Liabilities Increase From Notes Converted To Units
DerivativeLiabilitiesIncreaseFromNotesConvertedToUnits
4379000
CY2023Q3 cydy Warrant Equity Classified
WarrantEquityClassified
79000
CY2023Q3 cydy Fair Value Adjustment Of Derivatives
FairValueAdjustmentOfDerivatives
-4000
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
4375000
CY2023Q3 cydy Share Based Compensation Number Of Active Plans
ShareBasedCompensationNumberOfActivePlans
1
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.23
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
14700000
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
14700000
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
259910
CY2023Q2 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.37
CY2023 cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y6M25D
CY2023Q2 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
7276000
CY2023 cydy Class Of Warrants Or Rights Granted
ClassOfWarrantsOrRightsGranted
3009
CY2023Q2 cydy Class Of Warrants Or Rights Granted Weighted Average Exercise Price
ClassOfWarrantsOrRightsGrantedWeightedAverageExercisePrice
0.44
CY2023 cydy Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
3000
CY2023Q2 cydy Class Of Warrants Or Rights Exercised Weighted Average Exercise Price
ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice
0.10
CY2023 cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelled
3133
CY2023Q2 cydy Class Of Warrants Or Rights Forfeited Expired And Cancelled Weighted Average Exercise Price
ClassOfWarrantsOrRightsForfeitedExpiredAndCancelledWeightedAverageExercisePrice
0.75
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
256786
CY2023Q2 cydy Class Of Warrants Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingWeightedAverageExercisePrice
0.37
CY2023Q3 cydy Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y4M17D
CY2023Q3 cydy Class Of Warrants Or Rights Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAggregateIntrinsicValue
2860000
CY2023 cydy Class Of Warrant Or Right Outstanding And Exercisable
ClassOfWarrantOrRightOutstandingAndExercisable
256786
CY2023Q2 cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Exercise Price
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageExercisePrice
0.37
CY2023Q3 cydy Class Of Warrants Or Rights Outstanding And Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantsOrRightsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P4Y4M17D
CY2023Q3 cydy Class Of Warrants Or Rights Outstanding And Exercisable Aggregate Intrinsic Value
ClassOfWarrantsOrRightsOutstandingAndExercisableAggregateIntrinsicValue
2860000
CY2023Q3 cydy Stock Issued During Period Shares Warrants Exercised Cash
StockIssuedDuringPeriodSharesWarrantsExercisedCash
3000000.0
CY2023Q3 cydy Stock Issued During Period Value Warrants Exercised Cash
StockIssuedDuringPeriodValueWarrantsExercisedCash
300000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11571000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20991000
CY2022Q3 cydy Deemed Dividend Down Round Feature Decrease In Net Income To Common Shareholder Amount
DeemedDividendDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount
4154000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
373000
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
385000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11944000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
42600
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
46000.0
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
366000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
140000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
139000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
247000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
387000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
422000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
137000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
185000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
169000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
491000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
104000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
387000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100

Files In Submission

Name View Source Status
0001558370-23-016632-index-headers.html Edgar Link pending
0001558370-23-016632-index.html Edgar Link pending
0001558370-23-016632.txt Edgar Link pending
0001558370-23-016632-xbrl.zip Edgar Link pending
cydy-20230831.xsd Edgar Link pending
cydy-20230831x10q.htm Edgar Link pending
cydy-20230831xex10d1.htm Edgar Link pending
cydy-20230831xex31d1.htm Edgar Link pending
cydy-20230831xex31d2.htm Edgar Link pending
cydy-20230831xex32.htm Edgar Link pending
cydy-20230831_def.xml Edgar Link unprocessable
cydy-20230831_cal.xml Edgar Link unprocessable
cydy-20230831x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cydy-20230831_lab.xml Edgar Link unprocessable
cydy-20230831_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable